Pharmafile Logo

Pioneering Paths: Women Leadership in Rare Disease

Rare diseases are often thought of as affecting one in 100,000 or one in 1,000,000 people, and that is true for some conditions. But there are many rare diseases that are more common. It may surprise many to learn that a condition that’s considered rare has a prevalence of 1 in 2000 or lower, and rare diseases overall affect more than 300 million people worldwide.

- PMLiVE

When a rare genetic condition runs in your family, when you see the impact it has, and you grow up alongside a rare disease patient advocacy group started by your parents, you gain quite a lot of lived experience, says Lucy McKay, MD. “There was so much that I learned and saw.”

As McKay made her way through medical school she was disheartened to find that medicine and the NHS [National Health Service] were not receptive to her experience and accumulated knowledge. They didn’t recognize the common challenges in rare disease, they did not include rare disease patients in medical studies, and they weren’t preparing future clinicians to support rare disease patients and their families. “It was impossible for me to stay working in that environment,” McKay says. “I could not do the career I chose.”

So what to do? If you are McKay, you grab your medical degree and start the UK-based charity Medics4RareDiseases (and also become a steering committee member of Medscape Education’s rare disease initiative).  

In fact, she says, it’s not surprising that most rare disease advocacy leaders are women. “Approximately 70 to 75 percent of rare conditions present solely in childhood, and a similar proportion are genetic conditions. The caregivers are more likely to be female, see the signs earlier, and be living that experience with their child as their needs become more obviously understood. 

“When women get activated, what do they get activated by? In rare disease, it’s because these needs are wholly unmet,” says McKay. “There’s no one out there coordinating this drive to help their children or to help their other loved ones.” So women step in and start making a lot of noise because they have no choice.

Abigail Epstein, head of communications and patient advocacy for Takeda UK and Ireland, may not have grown up in a family of advocates, but she is no less passionate about helping to improve the lives of everyone affected by a rare condition in a world that really doesn’t understand their needs. “I’ve taken inspiration from the community, which has this incredible ability to work together for the betterment of one another and what needs to be done—against incredibly difficult odds. 

Epstein works on a campaign called I am number 17, to raise awareness of the fact that one in 17 people are affected by a rare disease at some point in their lifetime. Worldwide, rare diseases affect roughly 263 to 446 million people.  That statistic, Epstein says, originated from Genetic Alliance but was not well recognized outside the rare community. “As a group,” she says, “we wanted to change that. Because though individually rare, rare conditions are collectively common.” 

And things are starting to change, she says. That one in 17 statistic is now a common part of discourse when rare diseases are looked at. And now more than ever, pharmaceutical companies have a lot in the pipeline for rare diseases. 

The pharmaceutical industry is also leading the way when it comes to employing and supporting women. Though women are the driving force for change in rare disease, McKay and Epstein both acknowledge that the leap from kitchen table charity work to chairing a disease conference can be a hurdle. “When you start looking at organizations that work in rare that are profit-making or anyone who’s in a decision-making role, suddenly the room starts to become more male,” McKay says. “Even though this industry was built on female advocacy.” 

A 2021 workplace study from the Association of the British Pharmaceutical Industry “found that women make up more than 54% of the pharma workforce in England,” Epstein says. “At Takeda, I’m proud of the fact that 56% of the general managers across Europe and Canada are women. It’s really important to continue that momentum, encouraging women to pursue careers in science and technology, whether that be through mentorships or other opportunities, making a conscious effort to promote women into leadership.”

Hosted by Christy Rohani-Montez, PhD, Director of Clinical Strategy at Medscape Education Global

Follow us on LinkedIn for updates on upcoming podcasts and more insightful conversations.

For more information, please contact Jelena Spyropoulos (Global) or Piyali Shin (US).

To learn more about rare diseases, visit Medscape’s Pathways in Rare Disease, https://www.medscape.org/sites/advances/rare-diseases, Medics for Rare Diseases, m4rd.org, or I am Number Seventeen at iamnumber17.org.uk

About Medscape Education Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free accredited CME and CE courses for physicians, nurses, and other healthcare professionals.

 

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

Medscape Oncology and American Society of Clinical Oncology Collaborate to Offer Cancer-Specific Training to Multidisciplinary Members of the Oncology Care Team

This week Medscape Oncology announced an exciting collaboration with  ASCO® which you read on the Cision PR news wire here or below:The American Society of Clinical Oncology (ASCO®), a leader at...

Elevating Nephrology Outcomes at #ERA23

Medscape is headed back to Milano, Italy for the 2023 European Renal Association conference, #ERA23.This year, the team is elevating the outcomes of recent nephrology education programs to share the story...

Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023

The Medscape Education team will be on site at the 2023 EHA conference in Frankfurt, Germany to share the outcomes of recent hematology education programs and to advance the discussion on...

Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023

During the 2023 annual meeting of ACOG, Medscape highlighted the outcomes of CME/CE programs focused on improving clinicians knowledge and achieving better outcomes for patients. The outcomes were shared through...

Medscape Collaborates for Health Equity at DDW 2023

Recently, DDW 2023 took place in Chicago, IL, and Medscape was on-site with patient advocacy organizations to help educate clinicians on health equity in gastroenterology.Medscape was joined during the conference...

Real-World Impact of Continuing Medical Education on Physician Behavior in Prevention of Migraine

During the Alliance For Continuing Education in the Health Professions Industry Summit Medscape Education was awarded a Best in Class designation for its use of Real-World Outcomes to measure the impact of...

Medscape Present Outcomes of Neurology Education at AAN 2023

Medscape had education outcomes on the brain for this year’s AAN conference in Boston.During the conference, Medscape presented 5 scientific posters describing the impact of continuing medical education in migraine,...

Medscape Education Global Delivers Education and Outcomes to ECCMID 2023

Medscape Education Global has wrapped up its time in Copenhagen at ECCMID 2023. During the conference, Medscape Education Global had the opportunity to engage learners with an educational symposium and...

Antithrombotic Therapy for Peripheral Artery Disease: Medscape Education and Outcomes

At this year’s ACC2023 event, the Medscape Education team shared 7 posters highlighting the outcomes of cardiology continuing medical education (CME) programs. These posters covered a variety of cardiology topics...

Putting Skin in the Game at AAD 2023

AAD has wrapped up in New Orleans, and the Medscape team have returned home from another successful conference.During the conference, Medscape hosted one educational symposium, Reframing the Management Approach for...